Entera Bio (NASDAQ:ENTX) Posts Earnings Results, Misses Expectations By $0.05 EPS

Entera Bio (NASDAQ:ENTX) announced its quarterly earnings data on Friday. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05), FiscalAI reports.

Entera Bio Stock Performance

Shares of NASDAQ:ENTX opened at $3.14 on Friday. The stock has a 50-day simple moving average of $2.88 and a 200-day simple moving average of $1.95. The stock has a market capitalization of $546.12 million, a P/E ratio of -8.05 and a beta of 1.48. Entera Bio has a 1 year low of $0.91 and a 1 year high of $4.20.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on ENTX. UBS Group set a $9.00 price target on Entera Bio in a research note on Friday, September 18th. Cantor Fitzgerald started coverage on Entera Bio in a report on Tuesday, September 22nd. They issued an “overweight” rating for the company. Leerink Partners assumed coverage on shares of Entera Bio in a research note on Friday, September 18th. They set an “outperform” rating and a $9.00 price objective for the company. Guggenheim began coverage on shares of Entera Bio in a report on Thursday, September 24th. They set a “buy” rating and a $11.00 price objective on the stock. Finally, Lifesci Capital initiated coverage on shares of Entera Bio in a research report on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Entera Bio currently has a consensus rating of “Moderate Buy” and an average price target of $9.60.

About Entera Bio

Entera Bio Ltd. is a clinical-stage biotechnology company developing orally administered therapies based on its proprietary platform for delivering large-molecule drugs, including peptides and proteins. The company’s technology is designed to address the challenges that typically limit the oral delivery of biologic medicines.

Entera Bio’s lead program is EB613, an oral tablet formulation of parathyroid hormone (PTH 1-34) being developed for the treatment of postmenopausal osteoporosis.